SCHEMBL21495080

SCHEMBL21495080

COc1ccc(COC(=O)Nc2nc(-c3cccc(N4CCOCC4)n3)cs2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.46
ALDH1A1 P00352 8/20 0.46
SMN1; SMN2 Q16637 6/20 0.46
LMNA P02545 4/20 0.46
HTT P42858 3/20 0.46
KDM4E B2RXH2 2/20 0.46
APP P05067 1/20 0.45
WNT3A P56704 1/20 0.44
MAPK1 P28482 4/20 0.43
GAA P10253 1/20 0.43
PTBP1 P26599 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
USP2 O75604 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ROCK1 Q13464 2/20 0.43
ADORA3 P0DMS8 1/20 0.43
CCNA2 P20248 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21495070 0.88 WNT3A (0.51) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL28519673 0.80 LMNA (0.44) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL21495079 0.77 MAPT (0.48) MAPTALDH1A1LMNAKDM4EWNT3A
SCHEMBL21495084 0.74 MAPT (0.53) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL21505830 0.73 MAPT (0.45) MAPTALDH1A1LMNAKDM4EWNT3A
SCHEMBL21484611 0.72 WNT3A (0.48) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL21495060 0.69 ALDH1A1 (0.41) MAPTALDH1A1SMN1; SMN2HTTKDM4E
SCHEMBL9376371 0.69 LMNA (0.78) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL21484642 0.69 ALDH1A1 (0.44) MAPTALDH1A1SMN1; SMN2LMNAHTT
SCHEMBL18425338 0.67 ACHE (0.66) MAPTALDH1A1SMN1; SMN2LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases MASARYKOVA UNIVERZITA (CZ) 2023-02-21 US disclosed
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2022-01-06 US disclosed
WO-2019201865-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES MASARYKOVA UNIVERZITA (CZ) 2019-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11584742-B2 Substituted aminothiazoles as inhibitors of nucleases RNASEH1, DNASE1, FEN1 MAPT 706/4885ALDH1A1 2267/4885SMN1; SMN2 104/4885
US-20220002282-A1 SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF NUCLEASES RNASEH1, DNASE1, FEN1 MAPT 706/4885ALDH1A1 2267/4885SMN1; SMN2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.